We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.125 | 17.75 | 18.50 | 18.125 | 18.125 | 18.13 | 111,277 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.38 | 16.52M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/3/2017 17:28 | "It shows that for every 74 people given the drug for two years with statins, one heart attack, stroke or death would be prevented" ----- "But the cost is high - £4,400 a year per patient, compared with £20 statins " ----- I look forward to seeing what sort of reception CholBiome™ and CardioBiome™ receive. | loungeact | |
18/3/2017 17:17 | Shrewdie, this is the link..... | mouse20 | |
18/3/2017 17:08 | Shrewdmole, report in Daily Express I believe but expensive and has side effects. Also injection on a regular basis will put many people off. May be reports in other papers but consensus is no real impact on us I believe. More discussion on L*E to have a look at. | rafboy | |
18/3/2017 17:01 | Plas Do you have the link? S | shrewdmole | |
18/3/2017 16:44 | Parob The best part of that interview excert is his comment about the partner having the right incentive!! Ie they get 50% profit and haven't spent a mega multi million license amount. He's been there before!! Sm | shrewdmole | |
18/3/2017 16:42 | Did you see this BBC news report.Does this impact on our competitive position?'Huge advance' in fighting world's biggest killerAn injection cuts cholesterol to the lowest levels ever seen in medicine, in an international trial. | plasybryn | |
18/3/2017 16:35 | ODR, agree about the snack bars but I suppose you can't have everything in an initial launch of a new product. I read a report recently that said increased exercise leads to eating more and is not an effective way to lose weight. Your wife may find that cutting back on some of her exercise may reduce the hungry feeling. I know when I went through basic training I eat a mountain of food each day and lost so much weight my wife thought I was ill!! The point I am making is there needs to be balance in food intake and exercise. If you over exercise you will feel hungry if you restrict calories. Wish her well on her quest to lose some weight. | rafboy | |
18/3/2017 12:45 | Week One over for the wife on her GoFigure 3 week bundle diet. Positives ... Lost 3lb Visibly losing weight No snacking in week one Found ways of improving taste of shakes (thanks to suggestions here) Doesn't like the chocolate shake in any way Negatives ... Need more variety than just 2 types of snack bars With the considerable exercise she has also put in I think she was hoping for 4lb For the first time today she mentioned being hungry and a bit bored with the routine, I guess this is the will power part but thought it a little worrying she mentioned being hungry. Perhaps her body is still adjusting and it will pass as she moves into the second week. | onedayrodders | |
18/3/2017 12:40 | I think many PI's, were expecting some kind of deal on the cardio products last year. The deals have taken time for a reason. SOH has a fantastic strategy for the company. From the DT interview last month:"The key point to bring out to investors is that we don't see this as a single product opportunity, we see this as a multiple product opportunity with a range of partners. We've been working hard to ensure that we have multiple partners who have the right ability and the right incentive to take these products across a whole bunch of different territories. We see our strain, which we trademarked as LP-LDL, is very much the 'intel' inside a range of products for cardiovascular health across both consumer and pharma, this creates the opportunity for multiple revenue streams from the sale of the strain, the sale of white label products and the sale of branded products and that maximises shareholder return. So, whilst it's been a time-consuming process trying to put together multiple deals, it does diversify investor risk and if successful, would give a great shareholder return." | parob | |
18/3/2017 12:22 | Great post shrewdmole - spot on | whl2 | |
18/3/2017 12:16 | Elrico posts crossed so that wasn't in response to you btw!! Just getting very exciting here! | shrewdmole | |
18/3/2017 12:13 | Just wish I had more funds tbh! The investment case has always been compelling but now seems to be reaching what everyone has been asking for, commercialisation. There are a lot of companies out there with great tech and prospects which is why on aim Opti has t attracted more pi interest I guess. There's always the next new thing. Unless that is, you have spoken to soh or attended the presos. I have had the pleasure of both and the enthusiasm and surety has always been there. Have been on record here saying I reduced last year to utilise cash elsewhere but I'm back to an overweight position for me and will add further when funds allow. One thing that I believe has worked in Optis and our long term price targets is soh's previous lessons learnt on his last company sale. He has preferred to spend a longer period maximising the patent portfolio rather than rushing to get a product out. It's meant a year of range bound price action but imo will see both a sharper rise and a longer rise over the coming months and years as he roles out the different strains, partners and subsidiaries. It must have been hard when many pi's have been questioning his abilities and the ongoing discussions but now look. Tata as partner Sacco as partner Skin float in the not too distant future Go figure growing organically Sugar work progressing What else have we to look forward to? The mind boggles. So the above is why I did reduce but why this isn't just another aim growth potential game changer but an absolute must in anyone portfolio. Sm | shrewdmole | |
18/3/2017 11:51 | In the future I'll be grateful the price has been held back for a whole year by the likes of Seneca, YSF and David Evans as I've been topping up throughout, building up a substantial holding, as the investment case has got stronger and stronger, yet the price hasn't really risen. That is about to change over the next couple of months IMO which is why I took some more earlier this week. | parob | |
18/3/2017 11:35 | Elrico - I was privately estimating high single digits, so 13% is a fair bit higher. Your estimate is probably about right as not everyone is going to overstate their holdings, no one is likely to under-report their holdings, and there will be many more smaller holders that we don't know about, making up for any overstating. Pretty cool really. | lodger | |
18/3/2017 11:28 | Adam Reynolds only has 1.3M, well only, but 2.5M, this guy Parsnip says he holds, don't know about that. | lukead | |
18/3/2017 11:15 | lodger - If I am to assume PM disclosures are honest and Walter Mitty has played no part, it would be in excess of 13% and I don't include my modest holding in that stat. | elrico | |
18/3/2017 11:15 | Diamond, Who's said that Nobody that I can see | judijudi | |
18/3/2017 10:35 | This BB must hold at least 5% of OPTI :-) The chart is looking fantastic. | lodger | |
18/3/2017 09:17 | Strange that some one finds Elrico not very informative? I think he's one of the best on here. DIAMOND. | diamond fibre | |
18/3/2017 09:00 | Challenging 80p next week, indeed. And with snnouncents becoming more bullish by the week, what might an RNS on Tuesday or Wednesday bring with it? | owenmo | |
18/3/2017 08:13 | We now have:- 4 employees promoting our products.- Our European manufacturer Sacco promoting our LP-LDL strain - "Under the terms of the agreement, Sacco will promote and expand the supply of LP(LDL) (R) throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible."And soon we will have distribution partners doing their part in promoting our products - their PR and marketing departments will no doubt be very busy!The window of opportunity for cheap shares is getting shorter and shorter. | parob | |
18/3/2017 02:19 | Expect the share price to challenge 80p and above next week. Highest weekly close since July 2016. Technicals look excellent. | john henry | |
17/3/2017 23:33 | Parsnip, i am amazed at your revelation that you hold apx 2.5M shares in OPTI, making you one of the top shareholders | lukead | |
17/3/2017 22:27 | LOL - I fell asleep at 5 :-) | elrico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions